Laumas Sandeep 4

What Happened

• Laumas Sandeep, a director of Unicycive Therapeutics, received two restricted stock unit (RSU) grants on May 14, 2026: 84,200 RSUs and 42,100 RSUs, for a total of 126,300 RSUs. Each grant is reported at $0.00 per share (derivative award) and therefore shows $0 immediate cash value on the Form 4. These RSUs are payable solely in common stock when they vest.

Key Details

• Transaction date: 2026-05-14; Form 4 filed: 2026-05-18 (timely — within two business days).
• Reported consideration/price: $0.00 per share (derivative awards).
• Total RSUs granted: 126,300 (84,200 + 42,100).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes:
  • F1: The 84,200-share RSU award vests one-third on each anniversary of the grant for three years, subject to continued service.
  • F2: The 42,100-share Annual RSU vests one year after grant, subject to continued service.
• Transaction code: A = Award/Grant.

Context

• These are compensation awards (RSUs), not open-market purchases or sales; they don’t represent an immediate cash outlay or stock sale. RSUs convert into common shares only as they vest, so the economic benefit depends on future vesting and the company’s stock price at vesting. Such grants are common for directors and executives as part of compensation programs and should not be interpreted alone as a buy/sell signal.